应用SLC和Survivin共表达基因瘤苗抗肿瘤作用的研究  

Anti-tumour investigation on a DNA vaccine encoding SLC and Survivin antigen

作　　者：巴一[1] RALPHA.Reisfeld 

机构地区：[1]南京医科大学附属第一临床医学院肿瘤科,江苏南京210029 [2]Scripps研究所免疫教研室,lajolla加州美国92037

出　　处：《肿瘤防治杂志》2005年第8期561-564,共4页China Journal of Cancer Prevention and Treatment

基　　金：国家自然科学基金项目(30400538);江苏省人民医院引进人才基金(NA0404)

摘　　要：探讨应用次级淋巴趋化因子(secondary lymphoid chemokine, SLC)和Sur vivin共表达基因瘤苗抗肿瘤作用。方法:将SLC基因及Survivin 基因导入沙门氏菌载体,增殖并经口将此菌免疫荷瘤小鼠,观察抗肿瘤作用。结果: SLC/Survivin瘤苗对荷瘤小鼠具有较强的抗肿瘤作用。致死量D121肺癌细胞经尾静脉注入小鼠, 4 周后有87 .5% (7/8)的小鼠被证实无肿瘤生长。此保护性免疫反应可能是刺激CD8+ 细胞功能的发挥和细胞因子如γ干扰素等调节的。结论:SLC/Survivin瘤苗可诱导有效抗肿瘤反应,为将此类瘤苗使用于临床提供了一定的理论基础。OBJECTIVE:To investigate the anti-tumour effect of a DNA vaccine encoding SLC and Survivin antigen. METHODS: The mice were treated by oral gavage of this DNA vaccine carried by attenuated Salmonella typhimurium . RESULTS: A lethal challenge of D121 murine lung cancer cells were rejected in the experimental animals by the DNA vaccine, and 87.5% (7/8) of the mice were confirmed wthout tumor after 4 weeks. This vaccine induced tumor-protective immunity mediated by MHC class I restricted CD_8 + T cells. Activation of these T cells was indicated by increased secretion of proinflammatory cytokines such as INF-γ. CONCLUSIONS: The effect of anti-tumour response is induced by the vaccine. The result suggests this combination may be a promising strategy for the development of DNA-based cancer vaccines for future clinical applications.

关 键 词：癌症疫苗/免疫学 癌症疫苗/生物合成 趋化因子类 微管相关蛋白质类/生物合成 肿瘤细胞 培养的 

分 类 号：R730.3[医药卫生—肿瘤]